MedTrace Logo

Chemotherapy Combined With Radiation Therapy for Newly Diagnosed CNS AT/RT

NCT00084838 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 25

Last updated 2015-12-24

Study results available
· View outcomes & findings →

Summary

RATIONALE: Drugs used in chemotherapy work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Giving more than one chemotherapy drug with radiation therapy may kill more tumor cells.

PURPOSE: This phase II trial is studying how well giving intrathecal and systemic combination chemotherapy together with radiation therapy works in treating young patients with newly diagnosed central nervous system (CNS) atypical teratoid/rhabdoid tumors.

Conditions

  • Central Nervous System Tumor, Pediatric

Interventions

BIOLOGICAL

filgrastim

DRUG

cisplatin

DRUG

cyclophosphamide

DRUG

cytarabine

DRUG

dexrazoxane hydrochloride

DRUG

doxorubicin hydrochloride

DRUG

etoposide

DRUG

leucovorin calcium

DRUG

methotrexate

DRUG

temozolomide

DRUG

therapeutic hydrocortisone

DRUG

vincristine sulfate

RADIATION

radiation therapy

DRUG

Dactinomycin

Sponsors & Collaborators

Principal Investigators

  • Mark W. Kieran, MD, PhD · Dana-Farber Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2003-02-28
Primary Completion
2008-02-29
Completion
2013-03-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00084838 on ClinicalTrials.gov